Bitcoin Forms Super Predictive Golden Cross as Price Hits $7.5K – Bitcoinist

At last, bitcoin was able to break above the price ceiling that was keeping it from pursuing a more significant bull run.

The benchmark cryptocurrency jumped above $7,500 this Thursday in a surprising buying action that pushed the prices up by $704 in just three hours. It topped at $7,775 on Coinbase before correcting lower during the early Asian trading session Friday.

BTCUSD maintains gains above red bar resistance | Source: TradingView.com, Coinbase

The crypto has been able to navigate through the heavy resistance labeled on the chart seen above. Nevertheless, the interim price rally paused for a breather, indicating that traders are waiting for a bullish continuationbefore they buy bitcoin at local tops. It may lead to a sharp pullback to the downside.

As bitcoin aims to confirm an extended bull run, the cryptocurrency also has painted a historically accurate and super predictive Golden Cross.

The bullish indicator is formed when an assets short-term moving average closes above its long-term moving average. Bitcoin traders typically watch 50-daily and 200-daily MA curves to confirm a Golden Cross or its opposite, the bearish Death Cross. But those metrics have so far proven to be lagging.

In retrospect, the daily bitcoin chart forms a Golden Cross almost a month after the prices go up. Similarly, the cryptocurrency falls way before it paints a Death Cross pattern. That keeps traders from locating interim profitable opportunities.

But replacing 200-daily simple moving average with a 20-daily exponential moving average improves the predictive quality, as shown in the chart below via red circles.

BTCUSD 20-50 MA Golden and Death Crosses | Source: TradingView.com, Coinbase

The 20-50 MA combo instantly predicts bitcoins next potential moves. As of Friday, the 20-daily EMA is above the 50-daily SMA, hinting that the BTCUSD exchange rate is looking to head higher. A similar formation earlier this year had pushed the pair up by more than 40 percent.

So, in the current scenario, the bitcoin price can rise to as far as $10,000.

On the flip side, bitcoin is still trending higher inside a Rising Wedge pattern, as confirmed by two converging trendlines. The cryptocurrency could continue rising until it reaches the shapes apex. After that, it could fall by as much as the height of the Wedge, leading it below the $5,000 level.

Photo by Samuel McGarrigle on Unsplash

Read this article:

Bitcoin Forms Super Predictive Golden Cross as Price Hits $7.5K - Bitcoinist

Bitcoin Rallies 10% Ahead of CME April Futures Expiration – CoinDesk

Bitcoin prices spiked to a new monthly high of over $7,725, according to the CoinDesk Bitcoin Price Index. The rally comes on the day before the expiry for CME April bitcoin futures.

According to comments shared with CoinDesk, bitcoin traders view Friday's expiry as a primary catalyst for Thursday's rally. Theres a general expectation for a pickup in volatility around CME expiry, said Kevin Kelly, former equities strategist at Bloomberg and co-founder of Delphi Digital. But bitcoin was primed for a move given the recent consolidation, said Kelly.

Over $68 million worth of contracts were liquidated on BitMEX Thursday morning, according to data from Skew, as futures open interest is still recovering from a 50 percent plunge at the end of Q1 2020.

Bitcoins performance during a period of macroeconomic instability may be underwhelming for some investors. But Thursdays price action marks an over-100-percent recovery from bitcoins plunge at the end of Q1 2020.

Thanks to bitcoins strong macro fundamentals, were "seeing buying interest coming back, Kyle Davies, co-founder of Three Arrows Capital, told CoinDesk in a private message.

Traditional markets also rallied Thursday morning, with the S&P 500 up almost 2 percent at the time of publication.

As traders have been closely monitoring stocks, the push higher in U.S. equities today may share some responsibility for the jump in bitcoin's price, Joseph Todaro, managing partner at Blocktown Capital, told CoinDesk.

Stocks look really strong, another trader who expects bitcoin and equities to continue rallying together told CoinDesk in a private message.

Despite the highly volatile and tumultuous macro environment brought on by COVID-19, support for the popular bullish halving narrative may be resurfacing as traders become more comfortable within the current market, said Todaro.

The price of ether also spiked Thursday morning from $178 to $194, according to Bitstamp.

The leader in blockchain news, CoinDesk is a media outlet that strives for the highest journalistic standards and abides by a strict set of editorial policies. CoinDesk is an independent operating subsidiary of Digital Currency Group, which invests in cryptocurrencies and blockchain startups.

Read more here:

Bitcoin Rallies 10% Ahead of CME April Futures Expiration - CoinDesk

Bitcoin Price Hangs on to Key Support Level as Stocks and Oil Tip Over – Cointelegraph

The shockwaves from yesterdays explosion in the oil markets continued to damage oil prices and shrapnel from the blast caused damage to equities today as U.S. markets closed in the red after a nearly 3-week rebound.

West Texas Intermediate crude closed down 9.49% at $9.06, and June 2020 futures dropped from $22.58 to $13.12. What is clear is that investors remain fearful about the future of the entire industry as the coronavirus pandemic continues to dampen demand for oil.

Before the start of this week the S&P 500 and Dow had recovered approximately 30% of the losses from the Feb. 20 correction which quickly brought markets to historic lows. As shown on the 3-day chart below, the S&P 500 had rallied within a hair of the 61.8% Fibonacci retracement level, a point which many analysts forecast would be challenging to overcome.

Rejection at this level is likely to crush the narrative of a V-shaped recovery like the one witnessed in late December 2018.

SPX (S&P 500) 3-day chart. Source: TradingView

Traders who swear by the TD Sequential indicator will have also noticed that last Friday (April. 17) the market flashed a sell signal when a 9 appeared over the daily candle.

SPX (S&P 500) daily chart with 9 on TD Sequential. Source: TradingView

The Dow is in a similar position having met resistance at the 50% Fibonacci retracement which is slightly below the VPVR point of control at 246.22, a pivot point for the Dow. At todays close both indexes were down 5.07% and 5.30% respectively.

DOW (DIA) 3-day chart. Source: TradingView

For the past few weeks analysts from traditional markets have debated whether or not a strong recovery was in the making. Recently Goldman Sachs forecast that the current recession would be nearly 4 times worse than the 2008 housing crisis.

Meanwhile, pro business proponents from the Trump Administration have said that the current economic downturn is unsubstantiated as the markets will snap back to profitability once economic activity recommences.

Volatility indexes like the VIX, TVIX, and UVXY tell a different story as each gained 3.6%, 15.98%, and 12.06% for the day.

TVIX daily chart. Source: TradingView

In fact, all three have just finished their bottoming process after coming down from incredibly strong rallies that kicked off right as the coronavirus pandemic began to accelerate its rate of infections in late February. Take the above TVIX chart as an example.

Meanwhile, amidst the chaos in traditional markets, Bitcoin (BTC) price has remained relatively stable, ony pulling back 4.24% to what is so far proving to be a strong support at $6,850.

BTC USDT daily chart. Source: TradingView

At the time of writing the digital asset is attempting to re-enter the $6,900-$7,260 zone where the price spent the last 18 days trading. Re-entering this zone would be a positive step forward as the daily chart shows below the VPVR high volume node from $6,850-$6,600 Bitcoin is vulnerable to a drop to the $6,485 support and below this $6,200.

BTC USDT 4-hour chart. Source: TradingView

Another positive development is the pattern of higher lows and increasing buy volume on the 4-hour timeframe. If Bitcoin can reclaim the $6,900 level as support then the price can push above the Bollinger Band moving average at $7,055 and possibly exploit the small VPVR volume gap between $6,930-$7,050.

As discussed thoroughly in previous analysis, a push through the resistance cluster (pink) to flip $7,300 to support would open up the path for Bitcoin price to reach $8,000.

The views and opinions expressed here are solely those of the author and do not necessarily reflect the views of Cointelegraph. Every investment and trading move involves risk. You should conduct your own research when making a decision.

Read this article:

Bitcoin Price Hangs on to Key Support Level as Stocks and Oil Tip Over - Cointelegraph

Kim Jong-uns $2,000,000,000 Bitcoin (BTC), Crypto and Fiat Fortune Suddenly in the Spotlight – The Daily Hodl

Rumors of the death of North Korean leader Kim Jong-un have triggered a burst of speculation among Bitcoin (BTC) traders.

Data from the United Nations suggests North Korea has stolen approximately $2 billion worth of crypto and fiat currency from exchanges and financial institutions. The country has long been accused of being behind a number of sophisticated online heists in an effort to fund its military operations.

Russian Market, a Russian media blog, told its 159,000 followers on Twitter that reports of Kim Jong-uns ailing health could cause a BTC reversal if a change in command begins and officials decide its time to sell the countrys massive crypto holdings.

Economist Alex Krger says he highly doubts the death of Kim Jong-un is anything investors should worry about.

North Korea possesses uranium mines containing 4 million tons of high-grade uranium ore. North Korea news should trigger big selloff in Uranium (if Kims death confirmed).

As rumors continue to swirl about North Koreas supreme leader, South Korean intelligence says it has confirmedthat Kimis alive and well.

Wherever the truth lies, the Kim dynasty is set to continue. Kim Jong-uns sister, Kim Yo-jong, is next in line and would become the first woman to rule the country.

Featured Image: Shutterstock/Mc_Cloud

See the original post:

Kim Jong-uns $2,000,000,000 Bitcoin (BTC), Crypto and Fiat Fortune Suddenly in the Spotlight - The Daily Hodl

Bitcoin to the Rescue as Ron Paul Says US Fed Fake Economy Has Burst – Cointelegraph

The United States Federal Reserve fake economy has burst, former presidential candidate Ron Paul has announced as money printing takes its balance sheet to $6.6 trillion.

In a series of tweets on April 24, Paul became the latest critic to launch a scathing on U.S. economic policy present and past.

According to the pro-Bitcoin retired politician, neither coronavirus nor a brief uptick in stocks can hide the impact of the Feds actions. For him, Keynesian ideas such as market interventions and money printing are un-American.

The Fed's fake economy has burst. The stock market, even if it rises, cannot hide the damage that has been done. The virus, now known to be less deadly than the seasonal flu, cannot act as a legitimate excuse either, he wrote.

Another tweet read:

The un-American ideas of government micromanagement and Fed central planning of the economy have failed, and will continue to fail as long as they're clung to. The time to rebuild with the American ideas of liberty and sound money has arrived.

Pauls comments come as the Feds balance sheet reaches record highs of $6.6 trillion, purely due to money printing and associated economic bailout measures.

Federal Reserve balance sheet 14-year chart. Source: Holger Zschaepitz/ Twitter

As Cointelegraph reported, Raoul Pal, CEO of Global Macro Investor, this week released a dedicated 120-page report into the severity of the economic damage sparked by governments reaction to coronavirus.

The Baby Boomers are totally f*cked, a popular soundbite from the report, which champions Bitcoin, summarizes.

Meanwhile, the trader who called Bitcoin (BTC) topping at around $20,000 in 2017 has drawn comparisons to the stock markets of 2020 and 1930 just before the Great Depression hit with full force.

Comparing two Dow Jones charts, Peter Brandt argued that stocks current rise from last months crash merely echoes their behavior after the 1929 Wall Street Crash.

Sleep well tonight. We are all so lucky to be living in an age when Fed will bail us out, he sarcastically added in comments.

Dow Jones charts from 2020 and 1929-30. Source: Peter Brandt/ Twitter

The idea that money printing is ruinous in the long term has formed part of similar Fed criticism for almost a century.

The world is full of so-called economists who in turn are full of schemes for getting something for nothing, Henry Hazlitt wrote in his popular book, Economics in One Lesson, just a year after the Second World War.

They tell us that the government can spend and spend without taxing at all; that it can continue to pile up debt without ever paying it off, because we owe it to ourselves.

Read the rest here:

Bitcoin to the Rescue as Ron Paul Says US Fed Fake Economy Has Burst - Cointelegraph

Bitcoin halving explained: What is cryptocurrency event and will it boost price? – The Independent

For the first time in nearly four years, and for only the third time in its 11-year history, bitcoin is about to undergo a seismic shift to its technologicalfoundations. The halving event will not only affect how bitcoin is created, it will likely also have a significant impact on the entire cryptocurrency market.

Scheduled to take place next month, the event all stems from bitcoin's unique digital design. Unlike traditional currencies, the number of bitcoins that will ever exist is fixed. The mathematical code underpinning the cryptocurrency means that only 21 million bitcoins can ever be produced and no amount of quantitative easing can artificially inflate this.

More than 18 million bitcoins have already been produced through a process called mining, whereby new units of the cryptocurrency are generated by networks of computers programmed to solve complex mathematical puzzles.

Sharing the full story, not just the headlines

The imminent halving of bitcoin, however, is about to make this processconsiderably more difficult.

The halving event, sometimes referred to as thehalvening, is essentially the opposite of quantitative easing so much so that some crypto enthusiasts refer to it as quantitative hardening.

As the name indicates, the halving cuts the production of bitcoin in half in such a way that mining the cryptocurrency only generates 50 per cent of the yield it used to.

It takes place roughly once every four years whenever 210,000 blocks have been mined, and is predicted to take place on 12 May. This halving will see mining rewards fall from 12.5 bitcoins per block, to 6.25 bitcoins.

On 3 January, 2009, the genesis block of bitcoin appeared. It came less than a year after the pseudonymous creator Satoshi Nakamoto detailed the cryptocurrency in a paper titled 'Bitcoin: A peer-to-Peer Electronic Cash System'

Reuters

On 22 May, 2010, the first ever real-world bitcoin transaction took place. Lazlo Hanyecz bought two pizzas for 10,000 bitcoins the equivalent of $90 million at today's prices

Lazlo Hanyecz

Bitcoin soon gained notoriety for its use on the dark web. The Silk Road marketplace, established in 2011, was the first of hundreds of sites to offer illegal drugs and services in exchange for bitcoin

On 29 October, 2013, the first ever bitcoin ATM was installed in a coffee shop in Vancouver, Canada. The machine allowed people to exchange bitcoins for cash

REUTERS/Dimitris Michalakis

The world's biggest bitcoin exchange, MtGox, filed for bankruptcy in February 2014 after losing almost 750,000 of its customers bitcoins. At the time, this was around 7 per cent of all bitcoins and the market inevitably crashed

Getty Images

In 2015, Australian police raided the home of Craig Wright after the entrepreneur claimed he was Satoshi Nakamoto. He later rescinded the claim

Getty Images

On 1 August, 2017, an unresolvable dispute within the bitcoin community saw the network split. The fork of bitcoin's underlying blockchain technology spawned a new cryptocurrency: Bitcoin cash

REUTERS

Towards the end of 2017, the price of bitcoin surged to almost $20,000. This represented a 1,300 per cent increase from its price at the start of the year

Reuters

On 3 January, 2009, the genesis block of bitcoin appeared. It came less than a year after the pseudonymous creator Satoshi Nakamoto detailed the cryptocurrency in a paper titled 'Bitcoin: A peer-to-Peer Electronic Cash System'

Reuters

On 22 May, 2010, the first ever real-world bitcoin transaction took place. Lazlo Hanyecz bought two pizzas for 10,000 bitcoins the equivalent of $90 million at today's prices

Lazlo Hanyecz

Bitcoin soon gained notoriety for its use on the dark web. The Silk Road marketplace, established in 2011, was the first of hundreds of sites to offer illegal drugs and services in exchange for bitcoin

On 29 October, 2013, the first ever bitcoin ATM was installed in a coffee shop in Vancouver, Canada. The machine allowed people to exchange bitcoins for cash

REUTERS/Dimitris Michalakis

The world's biggest bitcoin exchange, MtGox, filed for bankruptcy in February 2014 after losing almost 750,000 of its customers bitcoins. At the time, this was around 7 per cent of all bitcoins and the market inevitably crashed

Getty Images

In 2015, Australian police raided the home of Craig Wright after the entrepreneur claimed he was Satoshi Nakamoto. He later rescinded the claim

Getty Images

On 1 August, 2017, an unresolvable dispute within the bitcoin community saw the network split. The fork of bitcoin's underlying blockchain technology spawned a new cryptocurrency: Bitcoin cash

REUTERS

Towards the end of 2017, the price of bitcoin surged to almost $20,000. This represented a 1,300 per cent increase from its price at the start of the year

Reuters

The event is not determined or governed by a centralised body.Instead,it is hard-coded into bitcoins underlying blockchain that was created in 2008 by its pseudonymous creator Satoshi Nakamoto.

Bitcoin was developed as an antidote to the perceived flaws in the established financial system, which had contributed to the global crisis of 2007-2008. By cutting the supply, the halving event is designed to ensure the scarcity of bitcoin while preventing extreme price inflation.

Previous halvings have resulted in sharp price increases and severe market volatility for bitcoin and other cryptocurrencies, as traders and miners adjust to the new production limitationsof the worlds most valuable virtual currency.

The halving in 2012 saw bitcoins value shoot up by 80 times, while the 2016 halving preceded a 300 per cent rise in bitcoins value. The simplest explanation for these price increases is the basic economic principle ofsupply and demand: if the supply suddenly drops but demand stays the same, the price will inevitably rise. But the decentralised and semi-anonymous nature of bitcoin means it is difficult to attribute specific gains or losses to a specific event.

Mays bitcoin halving comes in the middle of a global economic meltdown, though it is not yet clear whether collapsing markets is driving money away from traditional assets into cryptocurrency. Some analysts claim that bitcoin is becoming a safe-haven asset similar to gold, and early evidence suggests that investors may already belooking towards it as an alternative store-of-value.

The CEO of one of the worlds largest cryptocurrency exchanges recently revealed data showing a spike in deposits of $1,200 the exact same size as the US governments stimulus cheque.

Bitcoin is yet to be tested by global economic disruption on this scale, and it may well go the same way as stocks or other assets as investors rush to liquidate holdings into cash. Some analysts are hopeful, however, that the halving event combined with traditional market chaos could see the cryptocurrency reach above the record highs of $20,000 that it saw in 2017.

"Many eyes have been on bitcoin since the bull run of 2017, with people eagerly awaiting its next big moment. We believe that moment is coming and we can expect to see an explosive year for bitcoin," Danny Scott, CEO of British-based cryptocurrency exchange CoinCorner, toldThe Independent.

"With both the current unexpected global crisis and the halving event, we can only expect the price of bitcoin to continue in the direction that everything is currently pointing: towards that $20,000 figure and beyond."

Read more here:

Bitcoin halving explained: What is cryptocurrency event and will it boost price? - The Independent

Bitcoin Trades at $15k in Lebanon Amidst Economic Turmoil, Showing Its Real Potential – newsBTC

Bitcoin is trading almost twice its current rate in an economically-hit Lebanon.

Peer-to-peer bitcoin marketplace LocalBitcoins.com shows people selling the cryptocurrency for as high as22,678,227.03 LBP per token, which roughly equals $15,000. Meanwhile, people who are looking to liquidate bitcoin for local currency are demanding as much as $11,000 per token.

BTCUSD in Lebanon P2P markets jumps above $15,000 | Source: LocalBitcoins, Google

Exchange rates coming out of Lebonan crypto marketplaces are strikingly higher than their global counterparts. Data aggregator Messari shows the bitcoin price a little above $7,500 almost half than what is the Lebanese traders are asking.

Bitcoin hits its premium price levels in Lebanon as the country grapples with its most severe economic crisis in decades. The Lebanese Pound has crashed by almost 50 percent from its dollar-pegged value since October 2019, sparkinginflation, fueling social unrest, and locking Lebanese people out of their US dollar-enabled bank savings.

The central bank issued an order that allowed dollar account holders to withdraw money in local currency but before April 23. The ruling was meant to ease dollar demand but left people in a more panicked state. The country has one of the largest diasporas that send and receive funds in foreign currency.

Bitcoin peaked in Lebanon amidst the said chaos, validating the Al Jazeera coveragefrom late February that showed Lebanese opting for cryptocurrencies as a measure to protect themselves from inflation.

If you want to go around the banking system, bitcoin is a solution, a local crypto trader had told the news service.

The cryptocurrency operates outside the control of centralized authorities. A distributed group of miners offer their computing power to verify, validate, and add transactions to its open ledger called the blockchain. No single entity takes control over the Bitcoin network, making it an independent financial system.

Lebanons central bank discourages people from trading bitcoin, a reason why traders opt for peer-to-peer alternatives to buy and sell the cryptocurrency.

Bitcoins premium rates in Lebanon proves that locally there is more demand for the cryptocurrency than the available supply. People are purchasing it en masse to move out of their struggling fiat system, creating a parallel economy outside the scope of their government and central banks.

All and all, bitcoin has once again shown its real potential in a struggling national economy. Moreover, with the global one going into chaos as well, the cryptocurrency could emerge as a financial savior for an average saver.

Photo by Andr Franois McKenzie on Unsplash

View original post here:

Bitcoin Trades at $15k in Lebanon Amidst Economic Turmoil, Showing Its Real Potential - newsBTC

Bitcoin’s Tether Printer Divergence is Immensely Bullish; Here’s Why – Bitcoinist

Bitcoin has been experiencing some lackluster price action throughout the past several days and weeks, with the crypto hovering around the $7,000 region as its bulls and bears reach an impasse.

This boring price action has not corresponded with the massive issuance of stablecoins like Tether (USDT) leading some analysts to deem this as Bitcoins Tether printer divergence.

The phenomenon has been seen in the past and is historically followed by intense uptrends.

Bitcoin has been seeing some choppy trading between the upper-$6,000 region and the lower-$7,000 region for the past several days.

This has marked what appears to be a temporary end the cryptos firm uptrend that was sparked when it dipped to lows of $3,800 in early-March.

One interesting thing to be aware of is that the issuance of new stablecoins and USDT in particular has ballooned in recent times, signaling that these newly minted tokens will ultimately be cycled into Bitcoin and other cryptocurrencies.

The demand for these stablecoins could be coming from a myriad of difference sources, and one analyst believes that there are three primary suspects including wealthy Chinese, institutions looking to de-risk, and smart money accumulating a fixed supply hedge.

An unprecedented flood of stablecoin is being issued. Its likely liquidity for: -Chinese wealth bypassing capital controls -Institutions thatll de-risk on the next leg down -Smart money accumulating a fixed-supply hedge against collapse, he said while pointing to a chart showing the growth in USDT issuance.

Image Courtesy of Cole Garner

As for how this could impact the benchmark cryptocurrency, the same analyst refers to a phenomenon called Tether printer divergence to explain how it could be bullish.

BTC is experiencing Tether printer divergence. That story always seems to end the same way, he said while referencing the below chart.

Image Courtesy of Cole Garner

While looking at this chart, it does appear that USDT issuance front runs Bitcoins price action.

If history repeats itself, this means that the cryptocurrency could be poised for a major rally that is fueled by investors funneling these stablecoins into BTC.

Visit link:

Bitcoin's Tether Printer Divergence is Immensely Bullish; Here's Why - Bitcoinist

What Bitcoin SV signals to businesses, investors and social media – CoinGeek

Are you able to noticeBitcoin SVs signals? If not, you have a problem. You might get left behind.

Whether you consider yourself an investor, user, developer, customer, speculator, business owner, influencer, or generally digital asset affine personBitcoin SV is whispering and screaming at you at the same time.

Bitcoin SVs signals to businesses

Bitcoin SV has set its protocol in stone, which means there is no need for businesses to worry about future protocol changes that might affect already built applications and implementations concerning Bitcoin SV. Businesses are safe to spend resources building on or using BSV.

All other digital assets not only plan to change their protocol but already alter it at this very moment, leaving businesses in danger to waste spent resources.

This is what developers do not understand inBTC,ETH, and other digital assets: businesses need stability.

Digital asset developers need instability though

There is a crucial discrepancy between the interest of businesses and the interests of developers concerning digital assets. While companies seek stability in digital assets, developers need instability to remain relevant for fixing the instability. Developers have no interest in building a set in stone protocol, as a once established protocol makes developers almost obsolete.

Bitcoin SV has managed to take away power from developers with its set in stone protocol. Therefore, the signal Bitcoin SV is sending out to businesses is: build here, we serve stability.

There is much more to know for businesses about Bitcoin SV, though. For example, BSV offers limitless scalability with unbelievably low transactional costs. Bitcoin SV is also not only a digital asset, but a computing network in general.

Ryan X. Charles, founder and CEO of Money Button, has pointed out Bitcoin SVs ability to become a computational beast:

Bitcoin is going to be by far the largest computer ever () And what you can do with the biggest computer in the world is: you can actually compute bigger numbers.

Listen, businesses. If you do not get this signalBitcoin SV being the largest computer everwe cannot help you. Nobody can.

What Bitcoin SV signals to investors and speculators

Speculating and investing in the digital currency sphere has since at least three years ago been nothing but gambling. People read one single tweet about this or that nonsense-coin and bought in to sell minutes later to an even greater fool.

Why has investing and speculating in digital currencies never been a real thing, though?

It is due to the lack of utility in all digital assets except for Bitcoin SV. Speculating and investing makes sense, as long as you speculate on or invest in assets that have a use case for something. If there is no use case in an asset, is it even an asset? Come on.

How is speculating on the Bitcoin SV satoshis different? Those BSV satoshis are connected to the Bitcoin SV network, which processes transactions. Unlike other digital currencies, which have no serious transactional volume, Bitcoin SV is set up to process billions of transactions per year.

Why do Bitcoin SVs satoshis have a value, unlike all other digital currencies?

This is what the BSV satoshis are going to be needed for: transactions in the Bitcoin SV network by using apps and services, not trading on shady exchange servers.

Investing in Bitcoin SV is not limited to buying satoshis though. It is interesting to pay attention to the BSV ecosystem as a whole. For example, publicly traded TAAL Distributed Information Technologies Inc. has recently filed a patent concerning a blockchain computing device.

Bitcoin SVs network will not only be about processing payment transactions but also serve as a blockchain computer (such as described by Ryan X. Charles in the quote above). This is where TAAL seems to identify never seen before market opportunities.

This is what Bitcoin SV signals to investors and speculators: invest and speculate, but it is not about gambling.

What Bitcoin SV signals into the social media sphere

Nonsense-coins such as BTC, ETH, and the like desperately needsocial media, because they have to lure in new buyers to stabilize or pump the price. Bitcoin SV has no interest in being pumped or stabilized concerning fiat money, as it offers unique use cases, low-cost transactions, and stability. Anyone is free to make use of BSV in whatever way, but Bitcoin SV does not depend on social media influencers and bot-like social media users.

There have been vicious attacks on Bitcoin SV in social media, even in cooperation with crypto news sites and shady exchanges. We saw fake news, personal attacks, and delistings happening with an unprecedented intensity towards Bitcoin SV and its proponents. Thecrypto cartelspends millions to hinder Bitcoin SVs growth.

Does it work, though? Was the crypto cartel able to hold Bitcoin SV down? Good one. While crypto Twitter was tweeting, Bitcoin SV was building.

You may tweet all day long, that does not make you a user of Bitcoin. A user of Bitcoin is someone or something that generates a transaction on the Bitcoin network. Babbling on Twitter does not generate a Bitcoin transaction. You are helping Twitter, not Bitcoin.

Bitcoin SV signals to social media: we do not need you, but you can join the network.

Receive the signals, act accordingly

If you can hear Bitcoin SVs signals, you are already in the network. Prolific Bitcoin thinkerDaniel Krawiszhas stated:

Everything is falling into the Bitcoin SV black hole

for a reason. Utility, growththose are the keywords you need to figure out.

New to Bitcoin? Check out CoinGeeksBitcoin for Beginnerssection, the ultimate resource guide to learn more about Bitcoinas originally envisioned by Satoshi Nakamotoand blockchain.

Here is the original post:

What Bitcoin SV signals to businesses, investors and social media - CoinGeek

Bitcoin Email Scams 2020: Threatening Blackmail Tactics Used to Demand BTC | Featured – Bitcoin News

The number of bitcoin email scams has been growing in 2020 and the authorities in several countries have warned of new blackmail tactics used in threatening email scams asking for bitcoin. As the world scrambles to cope with the coronavirus pandemic and economic crisis, email scams are taking advantage of peoples fear to extort bitcoin.

The coronavirus crisis has caused a lot of panic and scammers are taking advantage of peoples fear. Those looking to blackmail victims for bitcoin know no borders as bitcoin blackmail email scams have been reported in a growing number of countries.

Fraudsters are leveraging increased fear and uncertainty during the covid-19 pandemic to steal your money and launder it through the complex cryptocurrency ecosystem, the U.S. Federal Bureau of Investigation (FBI) recently warned. The federal agency has seen a rising number of email scams asking for bitcoin payments. Noting that these email scams attempt to blackmail victims using various alarming tactics, the FBI described:

With the advent of covid-19, there is a new twist on this scam. The correspondence claims that the writer will both release your information and infect you and/or your family with coronavirus unless payment is sent to a bitcoin wallet.

Besides the emergence of coronavirus-focused email scams, sextortion email scams asking for bitcoin have also been on the rise in 2020, even though they are not a new tactic. People have shared their stories on social media of receiving bitcoin sextortion emails, such as on Facebook, Twitter, and Reddit. The U.K. and Canada are among the latest countries to see a rising number of sextortion email scam complaints asking for bitcoin.

With sextortion, scammers threaten to release steamy videos of the victim online. They may claim to have placed malware on a porn website visited by the victim, allowing them to record the targets screen with a webcam. The blackmail email then requests bitcoin or the steamy videos of the victim would be posted on social media. The Canadian Anti-Fraud Center recently explained:

A common sextortion email claims to have proof of you visiting a pornographic site and requests a bitcoin payment within 24-48 hrs or the content will be shared with your contact list.

In Canada, Halton regional police recently warned of fraudulent emails circulating in Southern Ontario attempting to extort bitcoin from residents. Investigators said that they have received more than 30 complaints about the same email, which reveals the recipients current or previous passwords and demands bitcoin. The email threatens to post an explicit video of the recipient online if a bitcoin payment is not made.

Besides sextortion, a bitcoin blackmail email scam can also threaten to spill the victims dirty secrets. The U.S. Federal Trade Commission (FTC) previously described this email scam tactic: Someone says they know about an alleged affair, or something else embarrassing to you, and demands payments with bitcoin or another cryptocurrency in exchange for keeping quiet. According to the FBI:

Threatening emails or letters in which scammers claim to have access to your personal information or knowledge of your dirty secrets and demand payment in bitcoin to prevent release of this information have been circulating for years.

There are several other threatening tactics that email scammers often use to extort bitcoin from victims. Ransomware scam emails used to be more prevalent but research has shown that its popularity has dwindled lately. Some scammers attempt to blackmail victims into handing over a bitcoin password to give them access to the coins.

Scammers will try to intimidate the victim, using threats and high-pressure tactics, to acquire immediate payment. The FTC said this action is not only a scam, but it is also a criminal extortion attempt. The agency urges anyone coming across such a scheme to report it to the authorities, such as local police, the FBI, the FTC, or their counterparts in other countries.

What do you think about all the bitcoin email scams in 2020? Let us know in the comments section below.

Image Credits: Shutterstock, Pixabay, Wiki Commons

Disclaimer: This article is for informational purposes only. It is not an offer or solicitation of an offer to buy or sell, or a recommendation, endorsement, or sponsorship of any products, services, or companies. Bitcoin.com does not provide investment, tax, legal, or accounting advice. Neither the company nor the author is responsible, directly or indirectly, for any damage or loss caused or alleged to be caused by or in connection with the use of or reliance on any content, goods or services mentioned in this article.

Read disclaimer

The rest is here:

Bitcoin Email Scams 2020: Threatening Blackmail Tactics Used to Demand BTC | Featured - Bitcoin News

Ethereum, XRP, Litecoin Turn Bullish on Bitcoins Strong Performance – Crypto Briefing

Investors appear to be growing optimistic about the future of the cryptocurrency market, which could lead to more upside price momentum. Key Takeaways

The cryptocurrency market is back in the spotlight after a bullish impulse pushed up prices for most digital assets. Indicators show further upward potential for Ethereum, XRP, and Litecoin, though important resistance levels are holding them down.

Since the Mar. 12 crash, Ethereum has been making a series of higher highs and higher lows. The bullish momentum has taken its price up more than 117%.

The smart contract giant surged from a low of $90 to a recent high of $190.

Despite the substantial price recovery over the last month, the TD sequential indicator estimates that Ether may have more upwards potential.

This technical index presented a buy signal the moment the current green two candlestick began trading above the preceding green one candlestick. If the bullish formation is validated by a further spike in demand, ETH could enter an upward countdown all the way up to a green nine candlestick.

Such a positive scenario seems likely given the amount of interest returning to the cryptocurrency industry, especially as Bitcoins halving event approaches.

Nonetheless, IntoTheBlocks In/Out of the Money Around Price model suggests that for Ether to continue reaching higher highs it would first need to move past the $200 resistance level. Approximately 1.2 million addresses bought nearly 7.8 million ETH around this price level.

An increase in the buying pressure behind Ether could allow it to break above this massive supply wall. If this happens, the bulls will likely take control of ETHs price action, validating the outlook presented by the TD sequential indicator.

Under such circumstances, the next levels of resistance to watch out are provided by the 127.2% and 161.8% Fibonacci retracement levels. These resistance barriers sit around $223 and $260, respectively.

Although everything seems to indicate that Ethereum has more room to go up, the global economic environment tells otherwise. Thus, an important support level to pay close attention to sits around the 78.6% Fibonacci retracement level and the rising trendline.

A daily candlestick close below $172 may invalidate the bullish outlook and increase the odds of a further decline towards $155 or $142.

For the first time since December 2018, the TD sequential setup suggests that it is time to buy XRP based on the 1-month chart. This technical indicator presented a bullish signal in the form of a red nine candlestick that has morphed into a green one candle due to the price action seen this month.

If Mays candlestick manages to move above Aprils monthly close, the bullish formation would likely be validated. This would indicate that XRP may surge for one to four monthly candlesticks or begin a new upward countdown.

Adding credence to the bullish outlook, the parabolic stop and reverse, or SAR, presented a buy signal on XRPs 1-day chart. Every time the stop and reversal points move below the price of an asset, it is considered to be a positive sign.

The parabolic SAR flip estimates that the direction of the trend for the cross-border remittances token changed from bearish to bullish.

Now, XRP would have to close above its 75-day exponential moving average to continue advancing further. By turning this resistance level into support, the odds for a move towards the 200-day exponential moving average, which sits around $0.23, increases substantially.

It is worth mentioning that XRP has been in a multi-year downtrend since the January 2018 peak. Since then, this altcoin is making a series of lower lows and lower highs. As a result, until it closes above the Feb. 15 high of $0.35, every bullish signal must be taken with caution.

Like the altcoins previously mentioned, Litecoin is also signaling that it is ready to resume its uptrend and climb higher. However, the 50-day exponential moving average is holding strong, preventing LTC from achieving its upside potential.

Since the beginning of the month, this barrier has been able to reject the price of Litecoin twice. Considering that resistance weakens the more times it is tested, sooner or later it could turn into support.

Breaking above the 50-day exponential moving average might send LTC towards the 100 or 200-day exponential moving average. These resistance levels sit at $49 and $54, respectively.

On the downside, however, investors pay close attention to the 23.6% Fibonacci retracement level since failing to hold could jeopardize the bullish outlook.

An increase in the selling pressure behind LTC that allows it to close below this support level could trigger a sell-off among market participants. Such a bearish impulse would likely send Litecoin down to try to find support around $39.

Regardless of the havoc that the pandemic has caused in the global financial markets, investors appear to be growing optimistic about what the cryptocurrency industry has to offer. Now, even Bloomberg analysts are bullish on Bitcoin, stating that this year it could transition toward a quasi-currency like gold.

The TIE has also seen an impressive rise in the number of Bitcoin tweets mentioning the halving. The cryptocurrency insights provider affirmed that halving mentions on Twitter surged over 63%. Meanwhile, the overall conversations on social media about BTC are up 6%.

As the block rewards reduction event approaches, the focus appears to be shifting towards Bitcoin. Nonetheless, the high levels of correlation in the cryptocurrency market suggest that an increase in the price of the flagship cryptocurrency could see the entire market following suit.

The information on or accessed through this website is obtained from independent sources we believe to be accurate and reliable, but Decentral Media, Inc. makes no representation or warranty as to the timeliness, completeness, or accuracy of any information on or accessed through this website. Decentral Media, Inc. is not an investment advisor. We do not give personalized investment advice or other financial advice. The information on this website is subject to change without notice. Some or all of the information on this website may become outdated, or it may be or become incomplete or inaccurate. We may, but are not obligated to, update any outdated, incomplete, or inaccurate information.

You should never make an investment decision on an ICO, IEO, or other investment based on the information on this website, and you should never interpret or otherwise rely on any of the information on this website as investment advice. We strongly recommend that you consult a licensed investment advisor or other qualified financial professional if you are seeking investment advice on an ICO, IEO, or other investment. We do not accept compensation in any form for analyzing or reporting on any ICO, IEO, cryptocurrency, currency, tokenized sales, securities, or commodities.

See full terms and conditions.

Read more:

Ethereum, XRP, Litecoin Turn Bullish on Bitcoins Strong Performance - Crypto Briefing

Crypto Market Sentiment is Back Up; Bitcoin, Ether in the Positive Zone – Cryptonews

Source: iStock/da-kuk

The market sentiment looks improved today compared to seven days ago. Following a small drop to 5.2/10 last week, the combined moving average 7-day market sentiment measure, sentscore, for the top 10 coins surpassed its highest level in the past five weeks - that of 5.27 from two weeks ago - and now stands at 5.37, as crypto market sentiment analysis service Omenics shows.

The week brings good news for all but one coin - only Tether (USDT) is in red this Monday. Meanwhile, after several weeks, we have two coins in the positive zone, these being first two coins by market capitalization: Bitcoin (BTC) and Ethereum (ETH). Five cryptos have sentscores above 5, three are above 4, and there are no coins in the negative zone.

The 24-hour time frame looks even better. This Monday is showing five out of ten coins in the positive zone, with Bitcoin reaching 6.9. Four are in the 5-5.9 range, and only Tether has a score of 4.7, but it too has gone almost 6% up today. In total, the combined sentscore for these 10 coins today is even closer to the positive zone: 5.86.

Sentiment change among the top 10 coins in the past week*:Interpreting the sentscores scale:- 0 to 2.5: very negative- 2 to 3.9: somewhat negative zone- 4 to 5.9: neutral zone- 6 to 7.49: somewhat positive zone- 7.5 to 10: very positive

Though the difference between them is small, three coins have seen green double-digit percentiles next to their names this week: Bitcoin Cash (BCH), EOS, and Stellar (XLM), respectively. BCH's highest score is in news (5.6). It got some lower scores in social and technicals (4.6 and 4.3), as well as negative scores in buzz and fundamentals (3.6 and 2.7). Similarly, EOS has a high score in news, with 6.4, as well as neutral scores of 5.4 in technicals and 4.6 in social, while its buzz and fundamental received 3.5 and 3.2, respectively. Stellar is a double winner today. Not only is it among the coins with the highest rise in sentscore this week, but that rise enabled it to push Chainlink (LINK) out of the top 10 list and take its place. It has two quite high scores of 7.1 and 7 in technicals and news, as well as a neutral 5.4 in social. Its buzz and fundamentals have negative scores though: 3.9 and 3.6.

Daily Bitcoin sentscore change in the past month:

The one coin that saw a percentile in red next to its name is today's losing coin. Tether's strongest point is news, which has a positive score of 6.3. It's followed by 5.5 in buzz, as well as 4.7 in technicals and 4.3 in social. Its weakest point this week is fundamentals, which got a negative score of 3.8.

Lastly, taking a look at the rest of Omenic's list besides the top ten coins over the course of the past seven days, we find an improved situation here as well. Compared to most of them last week, only 10 saw their sentscores drop this time around. Ten - one less than last week - have scores above 5, and one is even in the positive zone with a sentscore of 6: Nano (NANO). Two are in the negative zone, Komodo (KMD) and Steem (STEEM), and the rest are in the 4-4.9 range.

___

* - Methodology:

Omenics measures the market sentiment by calculating the sentscore, which aggregates the sentiment from news, social media, technical analysis, viral trends, and coin fundamentals-based upon their proprietary algorithms.As their website explains, Omenics aggregates trending news articles and viral social media posts into an all-in-one data platform, where you can also analyze content sentiment, later adding, Omenics combines the 2 sentiment indicators from news and social media with 3 additional verticals for technical analysis, coin fundamentals, and buzz, resulting in the sentscore which reports a general outlook for each coin. For now, they are rating 39 cryptocurrencies.

See more here:

Crypto Market Sentiment is Back Up; Bitcoin, Ether in the Positive Zone - Cryptonews

Bitcoin Association Publishes First Annual Report Highlighting Rapid Growth of Bitcoin SV Ecosystem – PR Newswire UK

LONDON, April 27, 2020 /PRNewswire/ -- Today, Bitcoin Association the global industry organization that works to advance Bitcoin SV publishes its first annual report, covering its operations from February 2019-20. The report highlights the rapid growth and development of the Bitcoin SV ecosystem, as well as the work the Association has undertaken in its first year of operations to support the network's underlying technical infrastructure and business expansion.

Interest in Bitcoin Association has rapidly grown as Bitcoin SV has captured the digital currency spotlight.The BSV blockchain has seen application development explode globally, as developers and businesses make use of BSV's superior scaling, data capacity and micropayment capabilities. Growing usage - particularly at the enterprise level - has led to a rise in the number of daily transactions and average block sizes seen on the network to now regularly surpass BTC on most days and BCH every day.

This growth of the Bitcoin SV network and ecosystem is reflected in Bitcoin Association's Year 1 annual report.Featuring a comprehensive description of the Association's mission to accelerate the business use of Bitcoin SV both as a blockchain and digital currency the report illustrates the multi-faceted approach that the organization has pursued under the leadership of Founding President, Jimmy Nguyen.

Split into 12 sections, the report looks at the great strides made by the Bitcoin SV network during the past year proving that Bitcoin can massively scale as Satoshi Nakamoto always intended and restoring the technical power of Bitcoin's original protocol.As summarized in the report, Bitcoin Association supports the Bitcoin SV Node team which works on the network infrastructure, is establishing a Technical Standards Committee, and is launching educational material and programs to train BSV developers.Bitcoin SV development activity has been robust with over400 known BSV ventures and projects around the world.

Additionally, the report recounts the Association's remarkable membership growth; its global ambassador and events programs; the contributions it is making to academia and public policy; as well as a look at its quickly growing team.

Speaking on the release, Mr. Nguyen commented: "Looking through the Annual Report, it really brings home just how much Bitcoin Association has accomplished in its first year. In such a short time, the Bitcoin SV network has experienced serious development and transaction volume increase demonstrating why it is the only blockchain with the capabilities required for enterprise use. We have been thrilled to see the Bitcoin SV community grow rapidly alongside us, with start-up entrepreneurs and now major enterprises alike demonstrating new use cases for BSV technology at an incredible rate. It's been a fantastic first year for the Association, but we're just getting started. We have an even bigger year planned for 2020 to bring Satoshi Vision to the world."

The report is available to download from Bitcoin Association's website.

About Bitcoin Association

Bitcoin Associationis the global industry organization which advances Bitcoin SV. It brings together enterprises, start-up ventures, developers, merchants, exchanges, service providers, blockchain transaction processors (miners),and others in the Bitcoin SV ecosystem to advance the growth of Bitcoin commerce. The Association seeks to build a regulation-friendly ecosystem that fosters lawful conduct while enabling digital currency innovation.

SOURCE Bitcoin Association

Here is the original post:

Bitcoin Association Publishes First Annual Report Highlighting Rapid Growth of Bitcoin SV Ecosystem - PR Newswire UK

A Tribute to Max Randell, Gene Therapy Pioneer – PLoS Blogs

I awoke on Monday morning to the sad news that Max Randell had passed away on April 18. He would have been 23 on October 9.

Maxie wasnt expected to live past the age of 8, or even much past toddlerhood, according to some doctors. But gene therapy, and his incredible family, had something to say about that. COVID-19 didnt claim him his body just tired of fighting.

Max Randells legacy is one of hope, to the rare disease community whose family members step up to participate in the clinical trials that lead to treatments. In this time of the pandemic, attention has, understandably, turned somewhat away from the many people who live with medical limitations all the time. Ill explore that story next week.

A Devastating Diagnosis

Max was diagnosed at 4 months of age with Canavan disease, an inherited neuromuscular disease that never touched his mind nor his ability to communicate with his eyes, even though his body increasingly limited what he could do. Fewer than a thousand people in the US have the condition.

Canavan disease is an enzyme deficiency that melts away the myelin that insulates brain neurons. Gene therapy provides working copies of the affected gene, ASPA.

Babies with Canavan disease are limp and listless. Most never speak, walk, or even turn over. Yet their facial expressions and responses indicate an uncanny awareness. A child laughs when his dad makes a fart-like noise; a little girl flutters her fingers as if they are on a keyboard when a friend plays piano. Theyre smart.

Today, with excellent speech, occupational, and physical therapy and earlier diagnosis, people with Canavan disease can live into their teens or twenties. Those with mild mutations live even longer.

Maxs passing is a tragedy, but he taught researchers about gene therapy to the brain. And that may help others.

Gene Therapy for Canavan

Max had his first gene therapy at 11 months of age and a second a few years later, after slight backsliding when clinical trials halted in the wake of the death of Jesse Gelsingerin a gene therapy trial for a different disease.

Ive written about Maxs journey through many editions of my human genetics textbook, in my book ongene therapy, and in several DNA Science posts, listed at the end.

Ive had the honor to attend two of Maxs birthday parties, which celebrate Canavan kids and the organization that his family founded, Canavan Research Illinois. At one party I brought along birthday cards that students whod read my gene therapy book made for him. And his grandma Peggy, who emailed me of his passing this past Monday, showed me how Max communicated with eyeblinks of differing duration and direction.

Heres what his mom Ilyce wrote about one yearly gathering:

This year will be the 20th Annual Canavan Charity Ball. Each year as I plan this event Im faced with the undeniable reality that theres a chance Maxie wont be here by the time the day rolls around. With each passing year this fear grows stronger and it becomes increasingly difficult to put into print that our annual event is in honor of Maxies birthday. Ive been talking to Maxie a lot lately about his life. He feels happy, strong, loved, content, productive, and fulfilled and he is looking forward to his upcoming 21st birthday. Im excited to celebrate this incredible milestone.

Maxs parents and brother Alex have had the unusual experience of time, of being able to watch their loved one as the years unfolded following gene therapy. They were able to see more subtle improvements than can the parents whose children have more recently had gene therapy to treat a brain disease. Parents watch and wait and hope that language will return, or that a child will become more mobile or less hyperactive, depending on the treated condition. The changes may be subtle, or slow, or restricted and thats what Max taught the world.

For him, the viruses that ferried the healing genes into his brain seem to have gathered at his visual system. His parents noticed improvements in the short term, just before his first birthday, as well as long term.

Within two to three weeks, he started tracking with his eyes, and he got glasses. He became more verbal and his motor skills improved. His vision is still so good that his ophthalmologist only sees him once a year, like any other kid with glasses. She calls him Miracle Max, Ilyce told me in 2010.

In 2016 I heard from Ilyce again:

I wanted to give you an update on Maxie. Hes going to be 19 on October 9th. He graduated from high school in June and is beginning a work program on Monday. Its been very exciting to watch him grow into a young man!

Max had an appointment with his ophthalmologist this week and his vision continues to improve. His doctor said that the gene is still active in his brain because his optic nerve shows absolutely no signs of degeneration and looks the same each year. I wish we could have been able to express the gene throughout more of his brain, but I am grateful for the treatments because of the progress hes made.

Even though gene therapy wasnt a cure for Max, the things we are experiencing definitely give me a lot of hope that once the delivery system is perfected, I can see a potential cure for Canavan disease in the future. Just knowing that the gene is still there 15 years later gives me confidence that a one-time gene transfer would actually work!

Maxs gene therapy circa 2002 targeted less than 1% of brain cells, with fewer viral vectors than are used to deliver healing genes in todays clinical trials. But it looks like some of the vectors may have made their way beyond the optic nerves, judging by the interest in math he had in high school and his critical thinking skills.

A Choice of Gene-Based Therapies

When the Randell family decided to pursue gene therapy, it was pretty much the only game in town. Thats changed.

Only two gene therapies have been approvedin the U.S. But a search at clinicaltrials.gov yielded 602 entriesdeploying the technology. The list still rounds up the usual suspects of years past mostly immune deficiencies, eye disorders, or blood conditions, with a few inborn errors of metabolism.

But one clinical trial mentions the gene-editing tool CRISPR, which can replace a mutant gene, not just add working copies as classical gene therapy does. TheCRISPRtrial is an experiment on stem cells removed from patients with Kabuki syndrome, which affects many body systems.

Spinal muscular atrophy now has two FDA-approved treatments, one an antisense therapy (Spinraza) that silences a mutation and the other (Zolgensma) a gene therapy that infuses copies of the functioning gene. Without treatment, the destruction of motor neurons in the spinal cord is usually lethal by age two.

In 2018, FDA approved the first drug based on RNA interference (RNAi), yet another biotechnology. It silences gene expression, which is at the RNA rather than the DNA level of the other approaches. Onpattro treats the tingling, tickling, and burning sensations from the rare condition hereditary transthyretin-mediated amyloidosis.

When I wrote my book on gene therapy in 2012, the technology was pretty much the only choice of research to pursue besides protein-based therapies like enzyme replacement. Now families raising funds for treatments for single-gene diseases can add antisense, RNAi, and CRISPR gene editing to the list of possibilities.

In any battle, a diversity of weapons ups the odds of defeating the enemy.

RIP Max Randell.

DNA Science posts:

Fighting Canavan: Honoring Rare Disease Week

A Brothers Love Fights Genetic Disease

Gene Therapy for Canavan Disease: Maxs Story

Celebrating the Moms of Gene Therapy

To support research:Canavan Research Illinois

Go here to see the original:

A Tribute to Max Randell, Gene Therapy Pioneer - PLoS Blogs

Merck KGaA to spend $110M on new gene therapy facility in California – BioPharma Dive

Dive Brief:

Merck KGaA, like other contract manufacturers such as Lonza, is betting the next big wave of demand will be for complex production of gene therapies and other products such as viral vaccines and immunotherapies. The gene therapy market will grow to about $10 billion by 2026 from $1 billion in 2018, the company said, citing estimates from Biotech Forecasts.

"Viral vector manufacturing has transitioned from a niche industry to the cornerstone of the future of biopharmaceuticals," said Udit Batra, head of Merck KGaA'slife science business, in a statement.

The German company has been on a spending spree in recent years, announcing plans to invest 1 billion euros in its global headquarters in Darmstadt, more than $400 million in two sites in Switzerland,and $70 million in a research and development hub expansion in Billerica, Massachusetts.

Carlsbad is already home to a Merck KGaA facility that has been involved in gene therapy since 1997, about the time that researchers beginning studying the potential for such treatments in people. At present, the site has 16 modular viral bulk manufacturing clean room suites and two fill/finish suites, Merck KGaA said.

With the new facility, the Carlsbad location will have 27 suites used in different parts of the manufacturing process and will support production at the 1000-liter scale using single-use equipment, Merck KGaA said.

The company also has a manufacturing facility in Glasgow that produces intermediates and final products for gene therapy and viral vaccines.

Merck KGaA, established in 1688, is majority owned by descendants of the original founder and had sales of 16.2 billion euros last year. The U.S. pharmaceutical giant Merck was once a subsidiary but is no longer associated with its German namesake.

Follow this link:

Merck KGaA to spend $110M on new gene therapy facility in California - BioPharma Dive

Vertex Pharmaceuticals and Affinia Therapeutics Establish Multi-Year Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies |…

DetailsCategory: More NewsPublished on Monday, 27 April 2020 15:42Hits: 68

Affinia Therapeutics proprietary AAV vector technology to be used in Vertexs genetic therapy efforts with focus on Duchenne muscular dystrophy, myotonic dystrophy type 1 and cystic fibrosis

BOSTON, MA & WALTHAM, MA, USA I April 27, 2020 I Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) and Affinia Therapeutics announced today that the two companies have entered into a strategic research collaboration to engineer novel adeno-associated virus (AAV) capsids to deliver transformative genetic therapies to people with serious diseases. Affinia Therapeutics proprietary AAVSmartLibrary and associated technology provides capsids for improved tissue tropism, manufacturability and pre-existing immunity. The collaboration will leverage Affinia Therapeutics capsid engineering expertise and Vertexs scientific, clinical and regulatory capabilities to accelerate the development of genetic therapies for people affected by Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and cystic fibrosis (CF).

This collaboration with Affinia Therapeutics will enhance our existing capabilities in discovering and developing transformative therapies for people with serious diseases, said Bastiano Sanna, Executive Vice President and Chief of Cell and Genetic Therapies at Vertex. Affinia Therapeutics innovative approach to the discovery and design of AAV capsids brings yet another tool to our Vertex Cell and Genetic Therapies toolkit, and were excited to partner with them to bring together their technology platform with our research and development expertise.

At Affinia Therapeutics, were setting a new standard in genetic therapy by leveraging our platform to methodically engineer novel AAV vectors that have unique therapeutic properties, said Rick Modi, Chief Executive Officer. Vertex is an established leader in developing transformative medicines for genetic diseases and renowned for its scientific rigor. We are thankful for the scientific validation this partnership brings and look forward to working closely with them to advance life-changing, differentiated genetic therapies and make a meaningful difference to those affected by these diseases.

About the Collaboration

Under the terms of the agreement, Affinia Therapeutics will apply its vector design and engineering technologies to develop novel capsids with improved properties. The agreement provides Vertex an exclusive license under Affinia Therapeutics proprietary technology and intellectual property (IP) in DMD and DM1 with an exclusive option to license rights for CF and an additional undisclosed disease. The scope of the agreement covers all genetic therapy modalities in these diseases. Affinia Therapeutics will be eligible to receive over $1.6 billion in upfront and development, regulatory and commercial milestones, including $80 million in upfront payments and research milestones that will be paid during the research term, plus tiered royalties on future net global sales on any products that result from the collaboration. Affinia Therapeutics will be responsible for the discovery of capsids that meet certain pre-determined criteria. Vertex will be responsible for and will fund the design and manufacturing of genetic therapies incorporating the selected capsids, preclinical and clinical development efforts, and commercialization of any approved products in the licensed diseases.

About Affinia Therapeutics

At Affinia Therapeutics, our purpose is to develop gene therapies that can have a transformative impact on people affected by devastating genetic diseases. Our proprietary platform enables us to methodically engineer novel AAV vectors and gene therapies that have remarkable tissue targeting and other properties. We are building world-class capabilities to discover, develop, manufacture and commercialize gene therapy products with an initial focus on muscle and central nervous system (CNS) diseases with significant unmet need. http://www.affiniatx.com.

About Vertex Pharmaceuticals

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) a rare, life-threatening genetic disease and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London, UK. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 10 consecutive years on Science magazine's Top Employers list and top five on the 2019 Best Employers for Diversity list by Forbes. For company updates and to learn more about Vertex's history of innovation, visit http://www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

SOURCE: Vertex Pharmaceuticals

Follow this link:

Vertex Pharmaceuticals and Affinia Therapeutics Establish Multi-Year Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies |...

Glaucoma can be successfully treated with gene therapy – Telangana Today

London:A common eye condition, glaucoma, could be successfully treated with a single injection using gene therapy, which would improve treatment options, effectiveness and quality of life for many patients, say researchers.

Glaucoma affects over 64 million people worldwide and is a leading cause of irreversible blindness. It is usually caused by fluid building up in the front part of the eye, which increases pressure inside the eye and progressively damages the nerves responsible for sight.

Current treatments include either eye drops, laser or surgery, all of which have limitations and disadvantages.

At present, there is no cure for glaucoma, which can lead to loss of vision if the disease is not diagnosed and treated early, said study researcher Dr Colin Chu from the University of Bristol in the UK.

For the findings, published in the journal Molecular Therapy, the research team tested a new approach that could provide additional treatment options and benefits.

The researchers designed a gene therapy and demonstrated proof of concept using experimental mouse models of glaucoma and human donor tissue.

The treatment targeted part of the eye called the ciliary body, which produces the fluid that maintains pressure within the eye.

Using the latest gene-editing technology called CRISPR, a gene called Aquaporin 1 in the ciliary body was inactivated leading to reduced eye pressure.

We hope to advance towards clinical trials for this new treatment in the near future. If its successful it could allow a long-term treatment of glaucoma with a single eye injection, which would improve the quality of life for many patients whilst saving the NHS time and money, Chu said

The researchers are currently in discussion with industry partners to support further laboratory work and rapidly progress this new treatment option towards clinical trials.

Link:

Glaucoma can be successfully treated with gene therapy - Telangana Today

Regenxbio Is A Leader In Gene Therapies – A Case Where The Platform Is Worth More Than The Pipeline – Seeking Alpha

Editor's note: Seeking Alpha is proud to welcome Numenor Capital as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA PREMIUM. Click here to find out more

Regenxbio (RGNX) is a pioneer in gene therapies with a wide set of licensing agreements and an internal pipeline. The company focuses on adeno-associated virus (AAV) gene therapies for gene replacement and antibody delivery pursuing markets in retinal, neurodegenerative, and liver diseases. With a market cap of ~$1.3B (enterprise value of ~$1B), ~$400M of cash on the balance sheet, and ~$35M in revenue, Regenxbio is well-positioned to complete its milestones around manufacturing and clinical development into 2020.

The core investment thesis for Regenxbio is described below.

Validated technology platform to develop successful AAV gene therapies:

Strong financial position:

Undervalued internal assets:

From its 52-week high, Regenxbio's stock is down over 40%. The stock reached a low point from COVID-19 development. This is likely due to a lack of near term catalysts for the stock. With additional data for their lead asset in wet AMD coming in the first half of 2020, the initiation of phase II trials for the asset, and the sales ramp up for Zolgensma, the stock has a few potential catalysts coming up. As a result, there is an attractive entry point for investors to become an owner in Regenxbio.

Figure 1: RGNX daily chart (Source: Capital IQ)

The opportunity is that Regenexbio's licensing agreement with AveXis (NVS) on a medicine called Zolgensma to cure spinal muscular atrophy can potentially alone earn Regenxbio $3B-$4B in revenue. Zolgensma is an AAV gene therapy that delivers a transgene of SMN1 to cure the disease. About 20K people in the US have the disorder. With the medicine being priced at a little over $2M per patient, the market potential is well over $40B.

In 2014, Regenxbio licensed their AAV technology to AveXis to cure spinal muscular atrophy. The deal included various milestone payments to Regenxbio and importantly a mid-single to low double-digit royalties on net sales.

This one deal alone beyond the 20 similar deals Regenxbio has and its internal pipeline makes the company an attractive business. A simple DCF analysis with various assumptions, with the most important being including a capital expenditure of $400M for the clinical work with their flagship internal product, supports that Regenxbio is undervalued:

Figure 2: DCF model for RGNX (Source: Internal)

All the modeling done doesn't really help anyone figure out why this opportunity exists? Why is Regenxbio undervalued? Doubts around the Zolgensma scale up? Worries that capital from licensing deals will be wasted on an internal drug pipeline?

It's unprecedented that a drug company's platform is worth a lot more than the internal pipeline of drugs. From Regenxbio's latest corporate presentation, the company's main internal program, RGX-314, is focused on wet AMD:

Figure 3: Overview of Regenxbio's main asset (Source: Corporate Presentation)

RGX-314 is an AAV therapy for wet AMD. The slide describes the problem (leaky blood vessels in the eye) and how large it is (~2M patients) along with the vector (AAV8) and delivery cargo (anti-VEGF Fab). However, the company doesn't mention Eylea or other wet AMD medicines that are already approved. Regenxbio alludes to issues around delivery of drugs like Eylea (REGN), but doesn't go too deep on this slide or the presentation in general about how competitive their RGX-314 program will really be amongst clinicians.

An important point for any gene therapy is delivery whether it's a transgene or a CRISPR protein. A major reason why Regenxbio focused on wet AMD and ophthalmology in general is that delivering something to the eye is a lot easier than delivering something to the brain. RGX-314 is undergoing a phase I/II trial focused on establishing safety; the pivotal trial will come later. For the phase I portion, the company met their primary endpoint and showed safety so far. They have also shown how increasing doses of their gene therapy reduces the number of injections. This is going to be an important experiment and data set to argue for clinicians to switch over from something like Eylea.

The real value in Regenxbio is in its AveXis deal and the various licensing partnerships:

Figure 4: Regenxbio licensing partnerships (Source: Corporate Presentation)

Figure 5: Regenxbio licensing partnerships (Source: Corporate Presentation)

Figure 6: Regenxbio licensing partnerships (Source: Corporate Presentation)

This business model is enabled by Regenxbio's core technology focused on AAV7-10 and natural or close-to-natural variants:

Figure 7: Overview of Regenxbio's platform (Source: Corporate Presentation)

Over the next two years, the key milestones are:

The business can continue to strike up more licensing deals and expand current ones. The margin of safety here is that Regenxbio is undervalued just for its deal with AveXis and its various licensing deals that provide periodic payments based on progress and potentially more royalties if the drugs are approved and commercialized.

This seems to be a case where the market is focusing on the company's internal pipeline. Regenxbio's headline drug is interesting but unlikely to be competitive. Whereas, the business has a wonderful platform and licensing business that is being ignored. Simple valuations show these cash flows are not being fully appreciated. As a result, Regenxbio is going to grow revenue without any additional work and still has the potential to strike again through the 20 or so deals it has.

Figure 8: Key upcoming milestones for Regenxbio (Source: Corporate Presentation)

Regenxbio's lead candidate is focused on wet age related macular degeneration (AMD). The disease is a severe form of macular degeneration, a condition in which layers of macula get progressively thinner. The wet form is caused by abnormal blood vessels grown under the macula and retina where leaky blood vessels cause problems with vision, ultimately leading to blindness. The current standard-of-care is an anti-vascular endothelial growth factor (anti-VEGF) therapy. Patients require monthly injection of anti-VEGF to stop the growth of leaky blood vessels. Wet AMD is not a genetic disease, but it is a large and established market for Regenxbio to capture.

To frame the market opportunity of wet AMD, a few facts are helpful:

196 million people worldwide & 288 million by 2040 have AMD

10% have wet AMD, but is the leading cause of blindness

175,000 new patients annually in US

Growing number of patients due to aging population

Current treatments are regular injections of anti-VEGF

Figure 9: Overview of wet AMD (Source: JMS)

For wet AMD, competition comes from Genentech, Regeneron (REGN), and Adverum (ADVM). Genentech sells Lucentis at a price of $1850 per dose. Regeneron sells Eylea at $1150 per dose. Genentech's Avastin is also used off lab and is becoming more popular due to its cheap price of $60 per dose; the medicine is currently used for metastatic colorectal cancer. For gene therapies in wet AMD, the sole competitor is Adverum Biotechnologies. With 20M people with wet AMD, the total market opportunity for these medicines are in the billions of dollars.

Where Genentech's and Regeneron's medicines require multiple doses over the lifetime of a patient, a gene therapy has the potential to be curative and remove the multiple dosing requirement. For wet AMD, over 50% recurrence rate in the first year after treatment has stopped, and over 25% recurrence rate in the second year after treatment has stopped For drugs like Eylea and Lucentis, monthly intravitreal injection creates large burden for patients and create difficulty in dosing for clinicians. These problems allow Regenxbio to potentially capture the market with a gene therapy:

Figure 10: Wet AMD market (Source: Reportlinker)

Regenxbio's lead asset, RGX-314 is pursuing wet AMD. So far the company has shown:

Dose dependent protein expression levels and drug efficacy

Sustained protein expression for over 1.5 years

Long term efficacy demonstrated for Cohort 3 for rescue-free patients

No serious adverse events (SAE), but mild adverse events (AE) such as inflammation

Significant improvement in visual acuity for rescue free patients

Figure 11: Trial design of Regenxbio's lead asset (Source: Corporate Presentation)

RGNX

Cohort 1

Cohort 2

Cohort 3

Cohort 4

Cohort 5

Dose

3 x 109 gc/eye

1 x 1010 gc/eye

6 x 1010vg/eye

1.6 x 1011 gc/eye

2.5 x 1011 gc/eye

Rescue Injection Free

Not Available

Mean 4.7 rescue inj.

Not Available

Mean 3.8 rescue inj.

3 / 6 Patients

Mean 1.3 rescue inj.

5 / 12 Patients

Mean 2.2 rescue inj.

9 / 12 Patients

Mean 0.8 rescue inj.

Duration

52 Weeks

52 Weeks

78 Weeks

52 weeks (2H 2020)

52 weeks (2H 2020)

Best Corrected Visual Acuity (BCVA)

In ETDRS letters

Mean: -2.0

Range: -8/+10

Mean: +7

Range: -4/+15

Mean: +8

Range: 0/+21

Mean: +2

Mean: +4

Central Subfield Thickness (m)

Mean: -14

Range -81/+92

Mean: +26

Range -7/+62

See the rest here:

Regenxbio Is A Leader In Gene Therapies - A Case Where The Platform Is Worth More Than The Pipeline - Seeking Alpha

UK Startup to Manufacture Cell and Gene Therapies with… – Labiotech.eu

The UK company MicrofluidX has closed a 1.6M (1.4 M) seed funding round to develop a microfluidic platform that could produce cell and gene therapies more cheaply than conventional cell cultures.

The funding round was led by UKI2S, a national seed investment fund targeting early-stage companies, as well as Longwall Ventures and Cambridge Angels.

MicrofluidX will use the funding to establish a prototype of its technology. With this prototype, the company then aims to compare the performance of its microfluidics approach to current cell culture techniques used to produce gene and cell therapies.

In the dynamic cell therapy space, one of the major bottlenecks facing the field is the manufacture and scaling process, as manual cell culturing techniques are often required. Applying microfluidic technology to the manufacturing process may be an answer to this issue.

Although it is less developed at the manufacturing level, microfluidics technology has long been part of research in cell biology. It has several advantages over conventional cell cultures. For example, it allows cell cultures to be controlled more precisely on chips, increases automation, and can reduce the consumption of expensive ingredients in the cell culture process by a factor of twenty.

According to MicrofluidX, its platform could scale up microfluidics far beyond just biology research. The aim is to run dozens of cell cultures in parallel, with the capacity to produce cells more cheaply and with a higher yield than with current manufacturing techniques.

The result is that we can leverage all the inherent advantages of microfluidic cell culture at a scale never seen before, MicrofluidXs founder and CEO, Antoine Espinet, told me. This leads to much lower bioprocessing costs, better control over the final product, and faster translation from research to commercialization.

In particular, the company is investigating its technologys capacity to produce immune T-cells a common type of cell used in immunotherapies such as CAR T-cell therapies and other cell types.

Whilst the regulatory agencies are now warming up to cell and gene therapies, there are still growing pains, especially around manufacturing, Pablo Lubroth, an investor with UKI2S, told me.

It is essential to not only support companies that produce the therapies themselves, but also companies that are developing enabling technologies to ensure these therapies can be effectively commercialized and therefore have a tangible benefit to the patient.

As well as manufacturing, microfluidics is gaining traction in diagnostics and screening. For example, another UK startup, Lightcast Discovery, was founded last year to screen cells using microfluidics and beams of light. Additionally, the Belgian nanofluidics company miDiagnostics last month raised 14M to commercialize its silicon chip diagnostics in collaboration with Johns Hopkins University in the US.

Image from Shutterstock

Originally posted here:

UK Startup to Manufacture Cell and Gene Therapies with... - Labiotech.eu

Sangamo- Early-Stage Progress in Gene Therapy – Yahoo Finance

Sangamo Therapeutics(SGMO) announced the official closing of the global deal withBiogen(BIIB) for gene regulation therapies in neurology, explains biotechnology sector expertJohn McCamant, editor ofThe Medical Technology Stock Letter.

More from John McCamant: Ziopharm: Catalysts in T-Cell Therapy

With roughly $650 million in cash post-deal, SGMO is trading just above its cash positive despite having the broadest pipeline in the gene therapy/editing/regulation field.

Of all things in the press release, management mentioned the cash would be used to progress the pipeline, plus the potential filing of a BLA for SB525 for hemophilia A.

Impressive Terms For Early Stage

As a reminder, Biogen paid Sangamo $350 million upfront, including a $125 million license fee and an equity investment in Sangamo stock of $225 million (@$9.21 per share).

Sangamo is also eligible to receive up to $2.37 billion in potential milestones, including $925 million on pre-approval milestones and $1.335 billion on first product sales (that does not include the royalties that are also part of the deal).

In the blockbuster markets being developed such as Alzheimers and Parkinsons diseases, SGMO will earn high-single-to-low double digit royalties on potential sales. This is a pre-IND stage deal remarkable financial terms for this early stage of development.

Hem A Update On Schedule

Pfizer(PFE) cancelled its R&D Day that was set for March due to the virus, but the Company will hold a quarterly earnings call on April 28. There is some chance that Pfizer updates investors with some of the highlights it was preparing for the R&D Day, including the SB-525 program with Sangamo.

Either way, SGMO will still be updating investors when the two longest treated patients in the ALTA study hit their 12-18 month follow-up for the duration of Factor VIII production, sometime this summer.

See also: Activision Blizzard: "Stay-at-Home" Entertainment

The 12-18 month durability data is key for SGMO given that BMRNs first 12-18 month durability data was the turning point for Wall Streets belief in their gene therapy. Sangamo is a buy under $20 with a target price of $30.

More From MoneyShow.com:

Visit link:

Sangamo- Early-Stage Progress in Gene Therapy - Yahoo Finance